Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$146.10 ▼ -0.28
(-0.19%)
MKT CAP: $14.88B • VOL: 1.32M
52W L $122 52W H $186
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$123
MEDIAN
$164
MEAN
$167
HIGH
$199
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NBIX TAPE
NBIX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $176.78 | $168.01 | 2025-02-14 | $132.95 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $184.09 | $172.40 | 2025-02-06 | $137.33 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $166.55 | $160.71 | 2025-01-29 | $140.26 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $149.02 | — | 2025-01-17 | $143.18 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $128.57 | $138.79 | 2025-01-09 | $130.03 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $173.86 | $151.94 | 2024-12-18 | $127.11 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $141.72 | $147.56 | 2024-12-04 | $135.87 | -4.3% | 48% | C |